Last reviewed · How we verify

arthritis — Treatment Landscape & Competitive Intelligence

arthritis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating arthritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Excedrin Extra Strength Pain Reliever NSAID Haleon Us Holdings Nonsteroidal Anti-inflammatory Drug [EPC] Cyclooxygenase 2004-01-01
TIDL PAIN RELIEF CRYOTHERAPY MENTHOL Cream CRYOTHERAPY Shenzhen Sam Technology Co., Ltd.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in arthritis
  2. Haleon Us Holdings · 1 drug in arthritis
  3. Shenzhen Sam Technology Co., Ltd. · 1 drug in arthritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in arthritis:

Cite this brief

Drug Landscape (2026). arthritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/arthritis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing